Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.0005 USD
Change Today 0.00 / 0.00%
Volume 7.8M
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

4700 Spring Street

Suite 304

La Mesa, CA 91942

United States

Phone: 619-702-1404

Fax:

Bio-Matrix Scientific Group, Inc., through its majority owned subsidiary, Regen BioPharma, Inc. (Regen), intends to engage primarily in the development of regenerative medical applications. The company intends to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which it would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. Principal Products and Services HemaXellarate I The company has begun development of HemaXellerate I, a cellular therapy designed to heal damaged bone marrow. HemaXellerate I is a patient-specific composition of cells that have been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies. The initial application of HemaXellerate I would be the treatment of severe aplastic anemia, which is characterized by immune-mediated bone marrow hypoplasia (underdevelopment or incomplete development of a tissue) and pancytopenia( reduction in the number of blood cells and platelets). HemaXellerate II Also in early stage development by the company is a version of HemaXellerate called HemaXellerate II.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMSN:US $0.00 USD 0.00

BMSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BMSN.
View Industry Companies
 

Industry Analysis

BMSN

Industry Average

Valuation BMSN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO-MATRIX SCIENTIFIC GROUP, please visit www.regenbiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.